Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06819891Phase 3Updated Aug 31, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
United States, Argentina, Australia, Austria, Belgium +22 more
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruiting
NCT07054190Phase 2Updated Aug 31, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Brazil, Canada, Germany +2 more
A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive Not Recruiting
NCT06934044Phase 1Updated Aug 28, 2026
Sponsor: Hoffmann-La Roche
Multiple Myeloma
China
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's DiseaseRecruiting
NCT06680830Phase 2Updated Aug 28, 2026
Sponsor: Neuron23 Inc.
Parkinson Disease · Parkinson · Idiopathic Parkinson Disease · Early Parkinson Disease (Early PD)
United States, Israel, Italy, Poland, Spain +1 more
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusRecruiting
NCT06704672NAUpdated Aug 28, 2026
Sponsor: Hoffmann-La Roche
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Poland, Turkey (Türkiye)
Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive Not Recruiting
NCT06068985Phase 2Updated Aug 28, 2026
Sponsor: Latin American Cooperative Oncology Group
Breast Cancer · HER2-positive Breast Cancer
Brazil
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive Not Recruiting
NCT00781612Phase 2Updated Aug 28, 2026
Sponsor: Genentech, Inc.
Neoplasm Metastasis
United States, Australia, Belgium, Brazil, Bulgaria +30 more
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsRecruiting
NCT06193252NAUpdated Aug 27, 2026
Sponsor: Radboud University Medical Center
Parkinson Disease · Prodromal Stage · Neurodegenerative Diseases · Parkinsonian Disorders
Netherlands
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII InhibitorsCompleted
NCT04158648Phase 3Updated Aug 27, 2026
Sponsor: Hoffmann-La Roche
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor · Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor · Hemophilia A
United States, Belgium, Canada, France, Germany +5 more
Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageRecruiting
NCT06993142NAUpdated Aug 27, 2026
Sponsor: Radboud University Medical Center
Parkinson Disease · Prodromal Stage · Neurodegenerative Diseases · Basal Ganglia Diseases
United States, Netherlands
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaActive Not Recruiting
NCT04077723Phase 1, Phase 2Updated Aug 27, 2026
Sponsor: Hoffmann-La Roche
Lymphoma, Non-Hodgkin
United States, Australia, Belgium, Canada, China +7 more
Identifying and Characterizing Preclinical MSRecruiting
NCT05787795N/AUpdated Aug 27, 2026
Sponsor: Yale University
Multiple Sclerosis
United States
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompleted
NCT04540211Phase 3Updated Aug 27, 2026
Sponsor: Hoffmann-La Roche
Esophageal Cancer
China, Hong Kong, South Korea, Taiwan, Thailand
Epidemiological Landscape of Cervical Cancer in Latin AmericaActive Not Recruiting
NCT04947605N/AUpdated Aug 27, 2026
Sponsor: Latin American Cooperative Oncology Group
Uterine Cervical Neoplasms
Argentina, Brazil, Dominican Republic, Peru
Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790MCompleted
NCT03133546Phase 2Updated Aug 26, 2026
Sponsor: ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer Metastatic
Ireland, Netherlands, Singapore, South Korea, Spain +1 more
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)Completed
NCT03644186Phase 2Updated Aug 26, 2026
Sponsor: ETOP IBCSG Partners Foundation
Breast Cancer · Estrogen Receptor Positive Tumor · HER2-positive Breast Cancer
Belgium, France, Italy, Switzerland
A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal CancerTerminated
NCT00642603Phase 2Updated Aug 26, 2026
Sponsor: Hoffmann-La Roche
Colorectal Cancer
United States
A Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminated
NCT02479386N/AUpdated Aug 26, 2026
Sponsor: Hoffmann-La Roche
Geographic Atrophy
United States, Argentina, Australia, Austria, Brazil +10 more
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement InhibitionActive Not Recruiting
NCT04654468Phase 3Updated Aug 26, 2026
Sponsor: Hoffmann-La Roche
Paroxysmal Nocturnal Hemoglobinuria
China
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive Not Recruiting
NCT04770896Phase 3Updated Aug 25, 2026
Sponsor: Hoffmann-La Roche
Unresectable Hepatocellular Carcinoma
Austria, Belgium, Brazil, Bulgaria, Canada +23 more
A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer PatientsCompleted
NCT05487248NAUpdated Aug 25, 2026
Sponsor: Jules Bordet Institute
Unresectable Locally Advanced Colorectal Cancer · Metastatic Colorectal Cancer · Candidate for Third-line or Subsequent Lines of Therapy
Belgium, France
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruiting
NCT05894239Phase 3Updated Aug 25, 2026
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer
United States, Argentina, Australia, Belgium, Brazil +24 more
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)Recruiting
NCT07137598Phase 2Updated Aug 25, 2026
Sponsor: Hoffmann-La Roche
Rheumatoid Arthritis
United States, Argentina, Belgium, Brazil, Denmark +7 more
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Active Not Recruiting
NCT02568267Phase 2Updated Aug 25, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer · Cholangiocarcinoma · Colorectal Cancer · Head and Neck Neoplasms
United States, Australia, Belgium, China, France +11 more
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)Recruiting
NCT05183035Phase 3Updated Aug 24, 2026
Sponsor: PedAL BCU, LLC
Acute Myeloid Leukemia
United States, Australia, Austria, Belgium, Canada +15 more

Previous page Next page